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ACE‐I

:   angiotensin‐converting enzyme inhibitor

AEBSF

:   4‐(2‐aminoethyl)benzenesulfonyl fluoride hydrochloride

BNP

:   5 μg/kg synthetic canine BNP 1‐32 given SC

BNP/FRUS

:   5 μg/kg synthetic canine BNP1‐32 and 2 mg/kg furosemide given SC

BNP1‐32

:   brain natriuretic peptide 1--32

BP

:   blood pressure

cGMP

:   cyclic guanosine monophosphate

CHF

:   congestive heart failure

DBP

:   diastolic blood pressure

EDTA

:   ethylenediaminetetraacetic acid

FRUS

:   2 mg/kg furosemide given SC

HR

:   heart rate

LLOQ

:   lowest limit of quantification

MBP

:   mean blood pressure

MMVD

:   myxomatous mitral valve disease

NPR‐A

:   natriuretic peptide receptor A

RAAS

:   renin‐angiotensin‐aldosterone system

SBP

:   systolic blood pressure

TP

:   total protein

UHPLC

:   ultra‐high‐performance liquid chromatography

UOP

:   urine output

UVTHS

:   University Veterinary Teaching Hospital, Sydney

1. INTRODUCTION {#jvim15416-sec-0007}
===============

Congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) is the leading cause of cardiac death in older, small‐breed dogs.[1](#jvim15416-bib-0001){ref-type="ref"} Medical treatment of CHF remains the predominant form of treatment in veterinary medicine, with current guidelines recommending a combination treatment consisting of a diuretic, an angiotensin‐converting enzyme inhibitor (ACE‐I) and an inodilator.[2](#jvim15416-bib-0002){ref-type="ref"} Though survival times using this treatment regimen have not yet been published, an estimation of around 1 year is considered standard among experts, based on extrapolations from clinical trials and retrospective studies evaluating survival outcomes on components of this treatment regimen.[3](#jvim15416-bib-0003){ref-type="ref"}, [4](#jvim15416-bib-0004){ref-type="ref"}, [5](#jvim15416-bib-0005){ref-type="ref"}, [6](#jvim15416-bib-0006){ref-type="ref"} The reasonably poor prognosis associated with this condition has prompted ongoing efforts in the discovery of additional or alternative therapeutics, including various inhibitors of the renin‐angiotensin‐aldosterone system (RAAS),[7](#jvim15416-bib-0007){ref-type="ref"}, [8](#jvim15416-bib-0008){ref-type="ref"} newer diuretics,[9](#jvim15416-bib-0009){ref-type="ref"}, [10](#jvim15416-bib-0010){ref-type="ref"} and surgical repair.[11](#jvim15416-bib-0011){ref-type="ref"}, [12](#jvim15416-bib-0012){ref-type="ref"}, [13](#jvim15416-bib-0013){ref-type="ref"}

In these research efforts, a somewhat neglected therapeutic target is the natriuretic peptide system. Brain natriuretic peptide (BNP1‐32) is an active component of this system. Binding to natriuretic peptide receptor A (NPR‐A) causes activation of guanylyl cyclase that converts the cytosolic nucleotide guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). From there, cGMP acts as an intracellular secondary messenger and causes diuresis, natriuresis, vasodilation, and RAAS antagonism. These are desirable properties to combat the progression of CHF and, indeed, experimental animal studies,[14](#jvim15416-bib-0014){ref-type="ref"}, [15](#jvim15416-bib-0015){ref-type="ref"}, [16](#jvim15416-bib-0016){ref-type="ref"}, [17](#jvim15416-bib-0017){ref-type="ref"}, [18](#jvim15416-bib-0018){ref-type="ref"}, [19](#jvim15416-bib-0019){ref-type="ref"}, [20](#jvim15416-bib-0020){ref-type="ref"} and early clinical trials in humans[21](#jvim15416-bib-0021){ref-type="ref"}, [22](#jvim15416-bib-0022){ref-type="ref"}, [23](#jvim15416-bib-0023){ref-type="ref"}, [24](#jvim15416-bib-0024){ref-type="ref"} have shown the benefits of BNP1‐32 in the treatment of CHF. This led to the registration of Nesiritide in the United States (Natrecor; Scios, Inc, Mountain View, California), a recombinant human BNP1‐32 product, for IV use in people with decompensated CHF displaying clinical signs of dyspnea at rest.

Despite its initial success, an ultimate reduction in the rate of case fatalities or rehospitalization was not observed in humans with CHF.[25](#jvim15416-bib-0025){ref-type="ref"} This caused Nesiritide to fall out of favor in human medicine and likely contributed toward reduced interest for use in companion animals. Another limiting factor is its formulation---an injectable preparation---which has traditionally resulted in use as an IV drug. Yet, there is growing evidence of its safety and efficacy when administered SC.[16](#jvim15416-bib-0016){ref-type="ref"}, [18](#jvim15416-bib-0018){ref-type="ref"}, [23](#jvim15416-bib-0023){ref-type="ref"}, [24](#jvim15416-bib-0024){ref-type="ref"}, [26](#jvim15416-bib-0026){ref-type="ref"}, [27](#jvim15416-bib-0027){ref-type="ref"} SC administration facilitates its use in chronic treatment, and its potential role in the treatment of subclinical heart disease[28](#jvim15416-bib-0028){ref-type="ref"} and in humans with diastolic dysfunction and right‐sided CHF[15](#jvim15416-bib-0015){ref-type="ref"}, [24](#jvim15416-bib-0024){ref-type="ref"}, [29](#jvim15416-bib-0029){ref-type="ref"} (Kwon et al., 2003; Tong et al., 2004; Zakir, 2005 \[abstracts\]) has also been explored. Although no solid conclusions to support its benefits in these contexts have been reported to date, there is enough theoretical and experimental data to support further investigation into its use in dogs with naturally occurring CHF caused by MMVD.

In this study, the cardiorenal and endocrine effects of synthetic canine BNP1‐32, given SC with or without furosemide, were evaluated in dogs with compensated CHF caused by MMVD.

2. MATERIALS AND METHODS {#jvim15416-sec-0008}
========================

2.1. Animals {#jvim15416-sec-0009}
------------

Seven client‐owned geriatric (10.5‐17 years old) male dogs with compensated American College of Veterinary Internal Medicine (ACVIM) stage C (chronic) CHF caused by MMVD were recruited in this study. Ethics approval was obtained from the University of Sydney Animal Ethics Committee before commencement of the study (approval number 2016/1113).

2.2. Study design {#jvim15416-sec-0010}
-----------------

This study was a single‐dose, cross‐over, pilot study evaluating the efficacy of synthetic canine BNP1‐32, given with or without furosemide, in the target population. It was conducted at the University Veterinary Teaching Hospital, Sydney (UVTHS) between May and September, 2017.

2.3. Enrolment criteria {#jvim15416-sec-0011}
-----------------------

Before enrolment, each dog had a screening examination which consisted of a review of the history, physical examination, and oscillometric blood pressure (BP) measurements (VetHDO; Memo Diagnostic, Darmstadt, Germany). Thoracic radiography, echocardiography, ECG, and select blood tests (alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, creatinine, glucose, albumin, globulin, total protein \[TP\], PCV, electrolytes) were also performed.

The inclusion criteria consisted of a diagnosis of CHF caused by MMVD and good control of clinical signs with pimobendan (Vetmedin; Boehringer Ingelheim Pty Ltd, North Ryde, NSW, Australia), benazepril (Fortekor; Elanco Australasia Pty Ltd, West Ryde, NSW, Australia), and furosemide (APO Furosemide; Apotex Pty Ltd, Macquarie Park, NSW, Australia). The exclusion criteria included previously diagnosed or suspected renal disease, adrenal disease, diabetes mellitus, systemic hyper/hypotension, primary or concurrent right‐sided CHF, and arrhythmias resulting in hemodynamic compromise. In addition, dogs were not enrolled if concurrent treatments with sildenafil, spironolactone, amlodipine, thiazide diuretics, or other medications that might interfere with cGMP metabolism, BP regulation, or renal function were required.

The diagnosis of CHF caused by MMVD was made on characteristic history and physical examination findings (dyspnea, tachypnea, or both responsive to treatment with furosemide; presence of abnormal lung sounds; at least a grade 4/6 systolic heart murmur loudest at the left apical region; and tachycardia on examination); echocardiographic evidence of severe MMVD and cardiac remodeling due to volume overload (ie, characteristic lesions of the mitral valves, severe mitral valve regurgitation, left atrial and ventricular enlargements) on an echocardiogram performed by a board‐certified veterinary cardiologist (Niek Beijerink); and radiographic evidence of cardiomegaly with left atrial enlargement, pulmonary edema, and pulmonary vasodilation. Two dogs did not have radiography performed before commencement of treatment for CHF. However, serial radiographies depicting pulmonary edema which resolved with commencement of treatment were available for the remainder of dogs enrolled.

2.4. Study outline {#jvim15416-sec-0012}
------------------

After enrolment, dogs presented to the UVTHS on 3 days, each 2 weeks apart, for this study. Benazepril was dosed once daily at night, including the night before each visit. The morning doses of pimobendan and furosemide were withheld on each study day. On the morning of each visit, history and physical examinations were performed to ensure well‐being of the dogs, and peripheral IV and indwelling urinary catheters were placed. At the end of a 1‐hour control period, heart rate (HR), BP, and urine output (UOP) were measured; blood and urine samples were collected for endocrine, electrolyte, biochemistry, and cGMP testing. The amount of blood collected was replaced with 7 mL saline. One of the following treatments was administered:BNP: 5 μg/kg synthetic canine BNP1‐32 (Canine BNP1‐32 \[011‐22\]; Phoenix Pharmaceuticals Inc, Burlingame, California) SC (visit 1)FRUS: 2 mg/kg furosemide (Ileum Furosemide; Troy Laboratory Ltd., Glendenning, NSW, Australia) SC (visit 2)BNP/FRUS: 5 μg/kg synthetic canine BNP1‐32 and 2 mg/kg furosemide SC (visit 3)

Treatment order was not randomized, and all dogs received all 3 treatments in the order listed above.

Measurement of HR and BP, collection of 7 mL blood, and IV administration of 7 mL saline were repeated at 1 and 3 hours after treatment. Measurement of UOP and collection of 5 mL urine were performed at 1, 2, and 3 hours after treatment. PCV and TP were monitored for safety purposes throughout. At the completion of this sampling period, IV and urinary catheters were removed, and dogs were treated with their usual morning medications (pimobendan and furosemide, if furosemide had not been given as a part of the treatment) and then fed. Dogs were then discharged home to continue routine medical treatment with pimobendan, benazepril, and furosemide, and owners were advised to monitor for any abnormalities to the injection site, changes in behavior, or development of signs of decompensated CHF until the next scheduled visit.

HR and systolic, diastolic, and mean BP (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], mean blood pressure \[MBP\]) were measured in triplicate and averaged before statistical analysis.

2.5. Sample processing and storage {#jvim15416-sec-0013}
----------------------------------

Blood samples were obtained via jugular venipuncture and immediately placed into plastic blood tubes containing EDTA (ethylenediaminetetraacetic acid) or lithium heparin. Urine samples were collected into sterile plastic urine tubes. EDTA‐anticoagulated blood samples and urine samples were immediately centrifuged at or below 4°C at 5500 relative centrifugal force (RCF) for 10 minutes for collection of plasma and sediment‐free urine. After obtaining a sample for PCV and TP, the lithium heparin‐anticoagulated blood samples were centrifuged at 4000 RCF for 4 minutes at room temperature for collection of plasma. For BNP1‐32 testing, additional protease inhibition was achieved by adding 1 mL EDTA plasma to a preprepared mixture of 4‐(2‐aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) and benzamidine (Sigma Aldrich, Castle Hill, NSW, Australia) to give a final concentration of 5 mM AEBSF and 10 mM benzamidine.[30](#jvim15416-bib-0030){ref-type="ref"} The remaining plasma and urine samples were also transferred into sterile, plain tubes and frozen for later analysis. Before analysis, samples were stored at −80°C for up to 136 days for BNP‐32; at or below −30°C for up to 144 days for cGMP; at −80°C for up to 125 days for sodium, potassium, and creatinine; and at or below −40°C for up to 270 days for aldosterone assays. Stability testing was not performed in this study; however, samples treated and held under similar conditions were reportedly stable in human plasma samples for 6 months for BNP‐32[30](#jvim15416-bib-0030){ref-type="ref"} and plasma and urinary cGMP.[31](#jvim15416-bib-0031){ref-type="ref"}, [32](#jvim15416-bib-0032){ref-type="ref"}, [33](#jvim15416-bib-0033){ref-type="ref"} Furthermore, aldosterone concentrations in human serum control samples stored at −30°C at the particular laboratory consulted for aldosterone assays were noted to be stable for at least 9 months, with no drift observed at 0.12 and 0.68 nM/L (n = 78).

2.6. Blood and urine analysis {#jvim15416-sec-0014}
-----------------------------

Plasma immunoreactive BNP‐32 concentrations were measured at a commercial laboratory (Phoenix Pharmaceuticals, Inc) using a validated[34](#jvim15416-bib-0034){ref-type="ref"} radioimmunoassay kit made by the company (BNP‐32 Canine RIA kit, RK‐011‐22; Phoenix Pharmaceuticals Inc). The samples were transported frozen to the laboratory, and each sample was assayed in duplicate and averaged for analysis.

Plasma and urine cGMP concentrations were assayed using a commercially available competitive enzyme‐linked immunosorbent assay kit using the manufacturer\'s guidelines (Parameter cGMP Assay, KGE003; R&D Systems Inc, Minneapolis, MN, USA). Low, medium, and high controls (QC54 cGMP controls; R&D Systems Inc) were added to each plate. Briefly, urine and plasma samples were thawed at room temperature, and 25 μL of each sample was mixed with 475 μL of diluent. Samples were further diluted 1:2 using the diluent provided if final concentrations exceeded the range of the assay. Of note, 100 μL of each standard, sample, and control were mixed with 50 μL of the cGMP conjugate and 50 μL of the primary antibody solution. After incubating for 3 hours on a microplate shaker at 450 rpm at room temperature, wells were washed 4 times, and 200 μL of substrate solution were added. This was incubated for 30 minutes in the dark, and 50 μL of stop solution were added. The plate was read using a microplate reader (Infinite M1000 PRO; Tecan, Männedorf, Switzerland) set at 450 and 540 nm. Readings made at 540 nm were subtracted from those made at 450 nm. A standard curve was generated using a 4‐parameter logistic curve fit using GraphPad Prism V7.02 (La Jolla, California). Measured concentrations were derived using this standard curve and multiplied by the dilution factor. All samples and standards were assayed in triplicate, all controls in duplicate, and results were averaged for analysis. All standard curves had R^2^ \> 0.987. The %CV of standard, sample, and control replicates were \< 10%, and the %CV of standards between plates were \< 10%. Each control fell within the expected concentration range. Plasma concentrations of cGMP were reported in pM/mL. In order to account for differences in concentration due to rate of urine production, urinary excretion of cGMP (UEcGMP; pM/kg/min) was also calculated by multiplying the UOP by the urinary concentration of cGMP.

Plasma and urine sodium (Na), potassium (K), and creatinine concentrations were measured at a commercial veterinary diagnostic laboratory (Veterinary Pathology Diagnostic Service, University of Sydney, Australia). Fractional excretion of sodium (FE~Na~) and potassium (FE~K~) were calculated using the formula:$${FE}_{X} = 100 \times \left( {\text{Urinary}\ X \times \text{Plasma\ creatinine}} \right)/\left( {\text{Plasma}\mspace{9mu} X \times \text{Urinary\ creatinine}} \right),$$where X indicates sodium or potassium.

Plasma concentrations of aldosterone were determined at the Radboud University Medical Centre laboratory (Nijmegen, the Netherlands) using a validated aldosterone assay involving ultra‐high‐performance liquid chromatography (UHPLC) coupled with tandem mass spectrometry (Rotteveel‐de Groot et al., 2018 manuscript in preparation). Briefly, 500 μL of plasma was prepared with protein precipitation, supported liquid extraction (Isolute SLE+; Biotage, Uppsala, Sweden) and solid phase extraction (Oasis HLB; Waters, Etten‐Leur, the Netherlands). Eluates were injected on an Agilent Technologies 1290 Infinity VL UHPLC system (Agilent Technologies, Santa Clara, California) equipped with a CSH Phenyl Hexyl (1.7 μm, 2.1 × 100 mm) analytical column (Waters) and coupled to an Agilent 6490 tandem mass spectrometer (Agilent Technologies). Settings included a capillary voltage of 3.0 kV, fragmentor voltage of 380 V, sheath gas temperature of 350°C, and gas temperature of 200°C. N~2~ was used as the collision gas. Aldosterone was quantified using both aldosterone‐d4 and aldosterone‐d7 internal standards (IsoSciences, Ambler, Pennsylvania). Two transitions (qualitative and quantitative) were measured for each analyte. The transitions (Q1 \> Q3) were *m*/*z* 366.1 \> 338.2 (15 kEV) and *m*/*z* 366.1 \> 194.1 (15 kEV) for aldosterone‐d7; *m*/*z* 363.1 \> 335.2 (15 kEV) and *m*/*z* 363.1 \> 190.1 (15 kEV) for aldosterone‐d4; *m*/*z* 359.1 \> 331.2 (15 kEV) and *m*/*z* 359.1 \> 189.1 (15 kEV) for aldosterone. The dwell time was 60 milliseconds. Sample concentrations were derived using a 7‐point calibration curve generated from aldosterone reference standards (Batch H158; Steraloids, Newport, Rhode Island) using Microsoft Excel and MassHunter (Agilent Technologies). All samples and standards were assayed in duplicate and averaged. The lowest limit of quantification (LLOQ) was estimated at 0.070 nM/L, with total %CV of 9.0 and 6.9 at 0.12 and 0.68 nM/L, respectively (n = 78).

2.7. Statistical analysis {#jvim15416-sec-0015}
-------------------------

Descriptive analysis consisted of visual inspection of trends over time and summary statistics. The median and range were reported. Genstat 16th edition (VSN International Ltd, Hemel) was used for statistical analysis. Data were evaluated for normality via inspection of Q‐Q plots. Where the data were not normally distributed, transformations (log~e~ for UOP, plasma immunoreactive BNP‐32 concentrations, FE~K~, urinary cGMP concentrations, urinary excretion of cGMP; Logit transformation for FE~Na~) were performed to approximate normality before statistical analysis.

Between‐ and within‐treatment effects were evaluated via linear mixed modeling with restricted maximum likelihood estimation using the following equation:$$\hat{Y} = \text{Treatment} + \text{Time} + \text{Treatment} \times \text{Time} + {Dog}\ {ID}\left( \text{random\ effect} \right) + \varepsilon.$$

Significance was set at α of 0.05. If the interaction term was significant, significant interactions were identified using the least square difference method post hoc. If this term was not significant, it was dropped from the model. Model assumptions were assessed through visual inspection of residual plots.

3. RESULTS {#jvim15416-sec-0016}
==========

Breeds represented in the study cohort included the Cavalier King Charles Spaniel (n = 2), Kelpie, Maltese cross, Jack Russell Terrier cross, and Miniature Poodle cross (n = 2). Baseline characteristics and doses of medications have been summarized in Table [1](#jvim15416-tbl-0001){ref-type="table"}. At the time of the first study day (visit 1), dogs had been on treatment with furosemide for a median of 59 days (range 18‐133 days), pimobendan for 63 days (range 26‐252 days), and benazepril for 33 days (range 16‐62 days). The median number of days between the diagnosis of CHF and the first study day was 59 days (range 18‐133 days).

###### 

Baseline characteristics at the time of screening in 7 dogs enrolled in the study

                                    Median   Range
  --------------------------------- -------- --------------
  Weight at screening (kg)          8.9      5.2‐14.4
  Age (y)                           12       10.5‐17
  Daily pimobendan dose (mg/kg/d)   0.45     0.32‐0.56
  Daily furosemide dose (mg/kg/d)   3.85     1.94‐5.06
  Daily benazepril dose (mg/kg/d)   0.32     0.17‐0.56
  LA : Ao                           2.3      1.8‐2.5
  wnLVIDd                           2.16     1.84‐2.44
  wnLVIDs                           0.95     0.83‐1.45
  FS (%)                            53       35.3‐56.9
  HR (bpm)                          120      114‐150
  SBP (mm Hg)                       138      120‐148
  DBP (mm Hg)                       80       66‐85
  MBP (mm Hg)                       100      92‐105
  BG (mg/dL)                        104.5    82.88‐120.72
  BUN (mg/dL)                       33.33    24.65‐48.74
  Crea (mg/dL)                      1.14     0.74‐1.67
  TP (g/dL)                         7.3      5.1‐7.8
  Albumin (g/dL)                    3.2      2.5‐4.2
  Globulin (g/dL)                   3.6      2.7‐4.5
  ALT (U/L)                         95       24‐293
  ALKP (U/L)                        101      12‐341
  Na (mEq/L)                        149      145‐153
  K (mEq/L)                         3.6      2.7‐4.2
  Cl (mEq/L)                        112      106‐120
  PCV (%)                           47       37‐54

Abbreviations: ALKP, alkaline phosphatase; ALT, alanine aminotransferase; BG, blood glucose; BUN, blood urea nitrogen; Crea, creatinine; FS, fractional shortening; HR, heart rate; LA : Ao, left atrium to aorta ratio; SBP/DBP/MBP, systolic/diastolic/mean blood pressure; TP, total protein; wnLVIDd/s, weight‐normalized left ventricular internal diameter in diastole/systole.

A deviation from the protocol occurred during visit 1 (BNP treatment) in 1 dog when urine samples were erroneously collected from the end of an extension line holding 10 mL of volume which was attached to the urinary catheter instead of emptying the contents of the line each time. As the line was filled with urine before collection of data, the measurement of UOP was not affected. However, the volume held in this line exceeded the amount of urine production in each hour; thus, urinary analyte concentrations did not accurately reflect expected concentrations for the period in which the sample was taken. As such, urinary endocrine, cGMP, and fractional excretions at visit 1 for this dog were not calculated, and these data were excluded from the overall analysis.

Administration of synthetic canine BNP1‐32 was well tolerated by all dogs in the study. There were no systemic or local adverse effects encountered during the study.

3.1. Effect of treatments on endocrine variables, cGMP, and fractional excretions {#jvim15416-sec-0017}
---------------------------------------------------------------------------------

The effect of each treatment on endocrine, cGMP, and FE~Na/K~ are depicted in Figures [1](#jvim15416-fig-0001){ref-type="fig"}, [2](#jvim15416-fig-0002){ref-type="fig"}, [3](#jvim15416-fig-0003){ref-type="fig"}.

![Plasma concentrations of immunoreactive BNP‐32 (pg/mL; graph A) and cGMP (pM/mL; graph B) after administration of BNP1‐32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1‐32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The median and range were plotted. Asterisks denote significant (*P* \< .05) differences between BNP1‐32 and furosemide (\*) and BNP1‐32 + furosemide and furosemide (\*\*\*). Hats denote significant (*P* \< .05) differences from baseline for BNP1‐32 (^∧^) and BNP1‐32 + furosemide (^∧^ ^∧^ ^∧^)](JVIM-33-462-g001){#jvim15416-fig-0001}

![Urinary excretion of cGMP (pM/kg/min; graph A) and fractional excretions of sodium (FE~Na~, %; graph B) and potassium (FE~K~, %; graph C) after administration of BNP1‐32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1‐32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The median and range were plotted. Asterisks denote significant (*P* \< .05) differences between BNP1‐32 and furosemide (\*); BNP1‐32 and BNP1‐32 + furosemide (\*\*); and BNP1‐32 + furosemide and furosemide (\*\*\*). Hats denote significant (*P* \< .05) differences from baseline for BNP1‐32 (^∧^); furosemide (^∧^ ^∧^); and BNP1‐32 + furosemide (^∧^ ^∧^ ^∧^)](JVIM-33-462-g002){#jvim15416-fig-0002}

![Plasma concentrations of aldosterone (nM/L) after administration of BNP1‐32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1‐32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The lowest limit of quantification (LLOQ) of the assay was 0.070 nM/L. All concentrations \< LLOQ were estimated to be half the LLOQ](JVIM-33-462-g003){#jvim15416-fig-0003}

Plasma concentrations of immunoreactive BNP‐32 rose significantly within an hour of BNP and FRUS/BNP treatments but not with FRUS (Figure [1](#jvim15416-fig-0001){ref-type="fig"}). Immunoreactive BNP‐32 levels returned to baseline by 3 hours after treatment.

Significant between‐treatment or within‐treatment effects were not observed with regard to plasma concentrations of cGMP, as indicated by the lack of a significant treatment‐time interaction (Figure [1](#jvim15416-fig-0001){ref-type="fig"}). In contrast to plasma concentrations of cGMP, a significant rise in UEcGMP occurred after administration of BNP and FRUS/BNP treatments, with observable differences arising between these treatments and FRUS (Figure [2](#jvim15416-fig-0002){ref-type="fig"}). Maximal effects were reached 1 hour after treatment and decreased to baseline levels by 3 hours after treatment. In contrast, UEcGMP reduced after FRUS treatment.

Both FE~Na~ and FE~K~ increased when dogs were given any treatment containing furosemide (Figure [2](#jvim15416-fig-0002){ref-type="fig"}). However, administration of BNP did not cause a significant change in these variables, and the addition of BNP did not result in significant changes in the excretion of these electrolytes when compared to treatment with furosemide alone.

Around 60% of plasma samples had aldosterone concentrations \< LLOQ. Because of this large number, only a descriptive analysis was performed. Traditional approaches for handling such data in bioanalytics include reporting values as missing, "rounding down" values to zero, or estimating these values to be half the LLOQ.[35](#jvim15416-bib-0035){ref-type="ref"} As the data was not missing, and as aldosterone concentrations would not be expected to be zero from a biological perspective, the value of half the LLOQ was assigned where concentrations \< LLOQ were obtained, and plasma aldosterone concentrations were graphically depicted (Figure [3](#jvim15416-fig-0003){ref-type="fig"}).

3.2. Effect of treatments on cardiorenal variables {#jvim15416-sec-0018}
--------------------------------------------------

The UOP increased significantly from baseline after administration of FRUS and FRUS/BNP and remained increased at the end of the study; in contrast, BNP alone did not result in changes to UOP (Figure [4](#jvim15416-fig-0004){ref-type="fig"}). Maximal effects were reached at 1 hour after treatment in the FRUS and FRUS/BNP groups, with a 1246% and 887% increase in median UOP compared to baseline, respectively. Though these treatments resulted in significantly higher UOP compared to BNP, there were no differences between the 2 furosemide containing treatments. None of the treatments resulted in significant changes in HR or BP (Figure [5](#jvim15416-fig-0005){ref-type="fig"}).

![Urine output (UOP) after administration of BNP1‐32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1‐32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The median and range were plotted. Asterisks denote significant (*P* \< .05) differences between BNP1‐32 and furosemide (\*); and BNP1‐32 and BNP1‐32 + furosemide (\*\*). Hats denote significant (*P* \< .05) differences from baseline for furosemide (^∧^ ^∧^) and BNP1‐32 + furosemide (^∧^ ^∧^ ^∧^)](JVIM-33-462-g004){#jvim15416-fig-0004}

![Systolic blood pressure (SBP; graph A), diastolic blood pressure (DBP; graph B), mean blood pressure (MBP; graph C), and heart rate (HR; graph D) after administration of BNP1‐32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1‐32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The median and range were plotted](JVIM-33-462-g005){#jvim15416-fig-0005}

4. DISCUSSION {#jvim15416-sec-0019}
=============

This is a report of a prospective study evaluating the cardiorenal and endocrine effects and tolerability of single doses of synthetic canine BNP1‐32 given SC to dogs with compensated ACVIM stage C CHF caused by MMVD. BNP1‐32 was well tolerated, and after subcutaneous dosing, it was well absorbed and resulted in an increase in UEcGMP; however, there were no measurable effects on biological outcomes (UOP, BP, HR, FE~Na/K~, and plasma aldosterone concentration) in this study. These findings are in contrast to results from dogs with experimentally induced CHF, and thus, raise questions regarding the potential for natriuretic peptide resistance in dogs with naturally occurring CHF.

In particular, derangements of intracellular pathways via which cGMP mediate natriuresis and diuresis might exist in dogs with CHF caused by MMVD. The rise in plasma concentrations of immunoreactive BNP1‐32 observed upon its administration confirms successful absorption from the site of administration. Appropriate binding to NPR‐A is demonstrated through the rise in UEcGMP accompanying any treatment containing BNP1‐32 but not furosemide alone. The validity of urinary and plasma concentrations of cGMP in demonstrating this interaction is evidenced by observations from numerous previous studies relating to this matter.[14](#jvim15416-bib-0014){ref-type="ref"}, [16](#jvim15416-bib-0016){ref-type="ref"}, [17](#jvim15416-bib-0017){ref-type="ref"}, [18](#jvim15416-bib-0018){ref-type="ref"}, [19](#jvim15416-bib-0019){ref-type="ref"}, [23](#jvim15416-bib-0023){ref-type="ref"}, [24](#jvim15416-bib-0024){ref-type="ref"}, [26](#jvim15416-bib-0026){ref-type="ref"}, [28](#jvim15416-bib-0028){ref-type="ref"}, [36](#jvim15416-bib-0036){ref-type="ref"}, [37](#jvim15416-bib-0037){ref-type="ref"}, [38](#jvim15416-bib-0038){ref-type="ref"}, [39](#jvim15416-bib-0039){ref-type="ref"}, [40](#jvim15416-bib-0040){ref-type="ref"} These changes in cGMP also make NPR‐A receptor downregulation less likely. The process of elimination thus renders downstream intracellular mechanisms a potential source of natriuretic peptide resistance in these dogs. Although the entirety of the pathways by which cGMP mediates cellular effects has yet to be discovered, there is evidence to support involvement of cGMP‐dependent protein kinases (PKG)[41](#jvim15416-bib-0041){ref-type="ref"}, [42](#jvim15416-bib-0042){ref-type="ref"}, [43](#jvim15416-bib-0043){ref-type="ref"} and amiloride‐sensitive cation channels[43](#jvim15416-bib-0043){ref-type="ref"} in the generation of natriuretic peptide‐induced vasodilation, natriuresis, and diuresis. In addition, phosphodiesterase 5 inhibition to reduce cGMP hydrolysis appears to be of benefit in the face of CHF and augments effects of exogenous BNP1‐32.[19](#jvim15416-bib-0019){ref-type="ref"}, [26](#jvim15416-bib-0026){ref-type="ref"}, [44](#jvim15416-bib-0044){ref-type="ref"}, [45](#jvim15416-bib-0045){ref-type="ref"}, [46](#jvim15416-bib-0046){ref-type="ref"}

Alternatively, the biological effects of BNP1‐32 might have been obscured in the present study due to aspects relating to its study design. The labeled use of Nesiritide in people is for acutely decompensated CHF, to be given as an IV bolus succeeded by a continuous rate infusion. In contrast, this study utilized an SC mode of delivery in dogs with compensated chronic CHF in order to minimize variability in clinical presentation and investigated the potential for its use in chronic treatment. Despite experimental studies showing effects of BNP1‐32 in chronic CHF,[18](#jvim15416-bib-0018){ref-type="ref"}, [23](#jvim15416-bib-0023){ref-type="ref"}, [24](#jvim15416-bib-0024){ref-type="ref"} it is possible that the lack of an overt state of volume overload might have resulted in lack of diuresis and natriuresis in this study, or that longer exposure to BNP1‐32 (either as a constant rate infusion or via multiple SC delivered doses of BNP1‐32) might have been required to produce detectable changes to cardiorenal variables. The noninvasive techniques of measuring BP and HR might have lacked the sensitivity to detect BNP1‐32 effects in such a small group of dogs, and only a limited number of cardiovascular variables were evaluated. Renal blood flow and measures of renal function other than UOP and FE~Na/K~ were not measured. The small number of sampling points might have also resulted in a failure to detect short‐lived effects. A crossover treatment design was used so that each dog acted as its own "control," thereby reducing variability and increasing chances of detecting treatment effects in this small cohort of dogs; however, the inclusion of a placebo treatment stream in which no furosemide or BNP1‐32 was given could have helped to highlight smaller treatment effects. Finally, a group of healthy dogs undergoing the same study procedures would have strengthened the conclusions drawn from this study and enabled direct comparisons to be made between healthy and diseased dogs.

The effect of BNP1‐32 on the spontaneous and furosemide‐activated RAAS in this population remains ill‐defined due to the majority of samples containing aldosterone concentrations below the LLOQ. With the reported range of plasma aldosterone concentrations being 20‐800 pM/L in dogs with naturally occurring CHF,[47](#jvim15416-bib-0047){ref-type="ref"}, [48](#jvim15416-bib-0048){ref-type="ref"} an LLOQ of 70 pM/L (equivalent to 0.07 nM/L) would appear to be adequate. Although in‐house stability testing showed prolonged stability of serum aldosterone, sample degradation in plasma remains a possible cause of these low concentrations. Alternative explanations include the chronicity of benazepril treatment (16‐62 days, with median 33 days) and the possibility for reduced RAAS activation in the chronic, stable phase of CHF.[49](#jvim15416-bib-0049){ref-type="ref"} Despite this, both treatments containing BNP1‐32 appeared to demonstrate an initial suppression and then a rise in aldosterone concentrations on visual inspection of Figure [3](#jvim15416-fig-0003){ref-type="fig"}. This observation is weak but is in contrast to previous reports of aldosterone suppression after BNP1‐32 administration in people with CHF[23](#jvim15416-bib-0023){ref-type="ref"} and in dogs with furosemide‐induced RAAS activation.[17](#jvim15416-bib-0017){ref-type="ref"} As a final note, the cGMP and aldosterone assays employed in this study should ideally have been fully validated for use on canine plasma and urine samples. Instead, formal validation was performed by the manufacturers of the assays utilizing samples from other species (humans and rodents), and partial validation and quality control monitoring of canine samples were employed during the course of this study. Yet, with the molecular structure of both cGMP and aldosterone being conserved between species, it is expected that the assays will perform similarly in samples from different species. These tests were thus deemed fit for use for the purposes of this study.

In summary, SC administered synthetic canine BNP1‐32 was well‐absorbed and increased UEcGMP in dogs with compensated CHF caused by MMVD. However, there were no biological effects on HR, BP, UOP, or FE~Na/K~, and BNP1‐32 did not augment effects of furosemide on UOP or FE~Na/K~. These findings suggest peripheral natriuretic peptide resistance and raise further questions regarding the role of BNP1‐32 in both the pathophysiology and treatment of CHF in dogs with MMVD.
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